GlassScriptPhysician profile
Emily A Mattingly
NPI 1013315019
$5,647.54
in general payments reported to CMS, 2019-2025
27 companies · $997 in 2025
The $997 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $601 · 2022: $1,068 · 2023: $2,232 · 2024: $749 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,841 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.54 |
| Education | $138.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,154.91 | 2021-2025 | Erleada, Tecvayli, Darzalex |
| Lilly USA, LLC | $610.99 | 2021-2025 | Verzenio, Jaypirca |
| Astellas Pharma US INC | $518.89 | 2021-2025 | Padcev, Xospata |
| Sobi, INC | $392.11 | 2022-2023 | |
| Genzyme Corporation | $348.25 | 2021-2023 | |
| Medtronic, INC. | $280.06 | 2022 | |
| Amgen INC. | $185.86 | 2022-2023 | Kyprolis, Lumakras |
| Regeneron Healthcare Solutions, INC. | $177.16 | 2021-2023 | Libtayo |
| Pfizer INC. | $174.77 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $168.14 | 2021-2024 | Onivyde |
| Exelixis INC. | $166.29 | 2023-2025 | Cabometyx |
| Incyte Corporation | $163.52 | 2021-2023 | Jakafi |
| Merck Sharp & Dohme LLC | $149.85 | 2023 | Keytruda, Lynparza |
| Seagen INC. | $141.00 | 2023 | Tukysa |
| Dendreon Pharmaceuticals LLC | $131.59 | 2025 | Provenge |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124.99 | 2023 | |
| Glaxosmithkline, LLC. | $124.99 | 2024 | Ojjaara |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2023 | Reblozyl |
| Dova Pharmaceuticals | $121.38 | 2021 | |
| Pharmaessentia USA Corporation | $107.83 | 2025 | Besremi |
| Puma Biotechnology, INC. | $75.00 | 2022 | |
| Caris Mpi, INC. | $73.04 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $67.60 | 2023 | Enhertu |
| Celgene Corporation | $19.68 | 2023 | Recothrom |
| Novartis Pharmaceuticals Corporation | $16.04 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.59 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Mattingly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.